Literature DB >> 15673748

Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro.

William B Wan1, James R Beadle, Caroll Hartline, Earl R Kern, Stephanie L Ciesla, Nadejda Valiaeva, Karl Y Hostetler.   

Abstract

Alkoxyalkyl esters of cidofovir (CDV) have substantially greater antiviral activity and selectivity than unmodified CDV against herpesviruses and orthopoxviruses in vitro. Enhancement of antiviral activity was also noted when cyclic CDV was esterified with alkoxyalkanols. In vitro antiviral activity of the most active analogs against human cytomegalovirus (HCMV) and orthopoxviruses was increased relative to CDV up to 1,000- or 200-fold, respectively. Alkyl chain length and linker structure are important potential modifiers of antiviral activity and selectivity. In this study, we synthesized a series of alkoxyalkyl esters of CDV or cyclic CDV with alkyl chains from 8 to 24 atoms and having linker moieties of glycerol, propanediol, and ethanediol. We also synthesized alkyl esters of CDV which lack the linker to determine if the alkoxyalkyl linker moiety is required for activity. The new compounds were evaluated in vitro against HCMV and murine CMV (MCMV). CDV or cyclic CDV analogs both with and without linker moieties were highly active against HCMV and MCMV, and their activities were strongly dependent on chain length. The most active compounds had 20 atoms esterified to the phosphonate of CDV. Both alkoxypropyl and alkyl esters of CDV provided enhanced antiviral activities against CMV in vitro. Thus, the oxypropyl linker moiety is not required for enhanced activity. CDV analogs having alkyl ethers linked to glycerol or ethanediol linker groups also demonstrated increased activity against CMV.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15673748      PMCID: PMC547274          DOI: 10.1128/AAC.49.2.656-662.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Incorporation of dietary lecithin and lysolecithin into lymph chylomicrons in the rat.

Authors:  R O Scow; Y Stein; O Stein
Journal:  J Biol Chem       Date:  1967-11-10       Impact factor: 5.157

2.  Alkoxy propane prodrugs of foscarnet: effect of alkyl chain length on in vitro antiviral activity in cells infected with HIV-1, HSV-1 and HCMV.

Authors:  G D Kini; J R Beadle; H Xie; K A Aldern; D D Richman; K Y Hostetler
Journal:  Antiviral Res       Date:  1997-09       Impact factor: 5.970

3.  Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir.

Authors:  Earl R Kern; Caroll Hartline; Emma Harden; Kathy Keith; Natalie Rodriguez; James R Beadle; Karl Y Hostetler
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

4.  Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir.

Authors:  Earl R Kern; Deborah J Collins; W Brad Wan; James R Beadle; Karl Y Hostetler; Debra C Quenelle
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

5.  Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection.

Authors:  Deborah J Bidanset; James R Beadle; W Brad Wan; Karl Y Hostetler; Earl R Kern
Journal:  J Infect Dis       Date:  2004-07-01       Impact factor: 5.226

6.  Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model.

Authors:  R Mark Buller; Gelita Owens; Jill Schriewer; Lora Melman; James R Beadle; Karl Y Hostetler
Journal:  Virology       Date:  2004-01-20       Impact factor: 3.616

7.  Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Vero cells.

Authors:  M C Connelly; B L Robbins; A Fridland
Journal:  Biochem Pharmacol       Date:  1993-09-14       Impact factor: 5.858

8.  Assembly of the endoplasmic reticulum phospholipid bilayer. Transporters for phosphatidylcholine and metabolites.

Authors:  Y Kawashima; R M Bell
Journal:  J Biol Chem       Date:  1987-12-05       Impact factor: 5.157

9.  Design and development of oral drugs for the prophylaxis and treatment of smallpox infection.

Authors:  George R Painter; Karl Y Hostetler
Journal:  Trends Biotechnol       Date:  2004-08       Impact factor: 19.536

10.  Studies on the substrate specificity of a carboxyl ester hydrolase from human pancreatic juice. I. Action on carboxyl esters, glycerides and phospholipids.

Authors:  D Lombardo; J Fauvel; O Guy
Journal:  Biochim Biophys Acta       Date:  1980-01-11
View more
  31 in total

Review 1.  Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents.

Authors:  Aswani D Vadlapudi; Ramya K Vadlapatla; Ashim K Mitra
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2012-04

2.  Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.

Authors:  Fernando J Bravo; David I Bernstein; James R Beadle; Karl Y Hostetler; Rhonda D Cardin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

3.  Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.

Authors:  Jacqueline Ruiz; James R Beadle; R Mark Buller; Jill Schreiwer; Mark N Prichard; Kathy A Keith; Kenneth C Lewis; Karl Y Hostetler
Journal:  Bioorg Med Chem       Date:  2011-03-23       Impact factor: 3.641

Review 4.  The search for new therapies for human cytomegalovirus infections.

Authors:  Mark N Prichard; Earl R Kern
Journal:  Virus Res       Date:  2010-11-21       Impact factor: 3.303

5.  Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus.

Authors:  Scott H James; Nathan B Price; Caroll B Hartline; E Randall Lanier; Mark N Prichard
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

6.  Alkoxyalkyl esters of (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine are potent inhibitors of the replication of wild-type and drug-resistant human immunodeficiency virus type 1 in vitro.

Authors:  Karl Y Hostetler; Kathy A Aldern; William B Wan; Stephanie L Ciesla; James R Beadle
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

Review 7.  Phosphonate prodrugs: an overview and recent advances.

Authors:  Kenneth M Heidel; Cynthia S Dowd
Journal:  Future Med Chem       Date:  2019-07       Impact factor: 3.808

Review 8.  Synthesis of nucleoside phosphate and phosphonate prodrugs.

Authors:  Ugo Pradere; Ethel C Garnier-Amblard; Steven J Coats; Franck Amblard; Raymond F Schinazi
Journal:  Chem Rev       Date:  2014-08-21       Impact factor: 60.622

9.  Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates.

Authors:  Mark N Prichard; Caroll B Hartline; Emma A Harden; Shannon L Daily; James R Beadle; Nadejda Valiaeva; Earl R Kern; Karl Y Hostetler
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

10.  Evolution of an amino acid based prodrug approach: stay tuned.

Authors:  Ivan S Krylov; Boris A Kashemirov; John M Hilfinger; Charles E McKenna
Journal:  Mol Pharm       Date:  2013-01-22       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.